Revised Article: Warfarin vs. Pradaxa and the Other New Anticoagulants (NOACs)
In May 2018, the FDA approval the reversal agent, Andexxa, for the NOACs Xarelto (rivaroxaban) and Eliquis (apixaban). Pradaxa (dabigatran) has had the reversal agent, Praxbind, since 2015.
This news sent us searching A-Fib.com for NOAC articles that might need to be updated. One such article is Warfarin vs. Pradaxa and the Other New Anticoagulants.
In the end we revised the entire article, which was originally written in 2015 with periodic revisions in 2016, 2017 and earlier this year.
Stay Informed. Know Your Choices.
Warfarin vs. Pradaxa and the Other New Anticoagulants is a good review of your anticoagulant choices, the risks and benefits of each, costs, and recent research on the side-effects of long time use of these blood thinners.
Partner with your doctor: Whether or not to go on an anticoagulant, and which one, is one of the most difficult decisions you and your doctor have to make. Stay up-to-date. Then you can partner with your doctor on a plan that meets your treatment goals.
Don’t forget: Your anticoagulant treatment choice may change over time (with lifestyle changes, interaction with other medications, getting older, etc). Go to: Warfarin vs. Pradaxa and the Other New Anticoagulants.
Educate yourself.
Become your own best patient advocate.